Genedrive Share Discussion Threads

[batiatus] 12/11/2024 19:33

Looks like people have still not learnt anything. It will be a small pump and dump at most.

The companies circumstance have not changed one bit. Monthly cash burn is still £400-600K. There have been no other sales besides the £100K 9 months ago.

The directors cannot expect to sit around all day taking a salary without providing any value to shareholders.

They need to prove the kits can sell and start making some profit.

As things stand, it's just a weeks after weeks without sales, only cash burn.

(G)enuinely (D)on't (R)ecommend

[hazl] 12/11/2024 19:10

Well done Genedrive.

[m_night10] 12/11/2024 19:02

POLX Polarean Imaging about to break out above 2p soon. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 155p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.

Putting this UK recovery play potential on radars.

1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.

APPROX 13P SHARE PRICE EQUIVALENT FOR POLX


2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M

APPROX 48P SHARE PRICE EQUIVALENT FOR POLX


3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.

APPROX 22P SHARE PRICE EQUIVALENT FOR POLX

4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout

POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice.

[atmysignal] 12/11/2024 16:20

Looks like rns logged for 7am

[porky9] 12/11/2024 15:56

@Batiatus
The short position is being closed - keep up

[minja19] 12/11/2024 15:40

chart looks pretty good on all fronts.
coiled spring as they say .. and patience

[atmysignal] 12/11/2024 15:34

3p test coming to a Level 2 near you

[hazl] 12/11/2024 15:32

Blue.

Not surprised.

[hazl] 12/11/2024 15:27

Hopefully momentum upward will continue.

[batiatus] 12/11/2024 12:50

The directors cannot expect to sit around all day taking a salary without providing any value to shareholders.

They need to prove the kits can sell and start making some profit.

As things stand, it's just another day without sales, only cash burn.

(G)enuinely (D)on't (R)ecommend

[hazl] 12/11/2024 12:14

I can also state with confidence that anyone buying today has to pay more than they did yesterday.
I know because I purchased yesterday and could sell them for more than that price today.
Resding between the lines has become more important than ever.

IMO

[hazl] 12/11/2024 11:37

At least 3 of those recent trades ought to be in the buy column in my opinion.

[hazl] 12/11/2024 11:25

Takeaways from the above

Would save 18 million for NHS Scotland.

The test kit has low test failure rate

It is of benefit to addressing any inequalities in healthcare.

[hazl] 12/11/2024 11:18

'Key conclusions of the SHTG assessment relevant to the Genedrive® CYP2C19 ID kit were as follows:


• Using the Genedrive® CYP2C19 ID Kit to identify clopidogrel resistance was resource saving from year two
onwards and would also prevent 961 recurrent strokes over a 5-year period and save NHS Scotland
approximately £18 million;



• The benefits of antiplatelet therapy are maximised when the patient is started on treatment within 24
hours of the initial stroke or TIA. Laboratory-based testing, which can take up to one week to provide
results, could result in patient harm if treatment is delayed until the test results are available and many
patients could be discharged from hospital by the time laboratory test results are available;

• Smaller hospitals serving remote and rural areas would experience problems accessing laboratory-based
genotype testing;

• There are four regional genetic testing centres in Scotland and they are under pressure to deliver urgent
cancer genetic testing priorities. There was concern that using regional genetic testing centres would result
in inequalities in care across Scotland; and

• The Genedrive® CYP2C19 ID Kit had low test failure rate and can identify more targets, which is a crucial
consideration for the inclusion of more patient s from a wider range of ethnic backgrounds and therefore aids adressing inequalities in healthcare'.

[hazl] 12/11/2024 11:17

.Dr Gino Miele, CEO of genedrive plc, said: “With recent NICE guidance recommending CYP2C19 genotyping
strategies in the UK NHS for IS and TIA patients in the NHS who are eligible for receiving the antiplatelet Clopidogrel,
and recommending our test as the point-of-care platform of choice, these initial first-sales of our CYP2C19 ID-kit in
the UK to one of the largest stroke centres nationally is a key initial milestone in our CYP2C19 commercialisation
strategy, and further strengthens our pharmacogenetic positioning strategy in emergency care more broadly. We
look forward to increasing implementation of our CYP2C19 test in the UK NHS and internationally to the benefit of
both healthcare systems financially and improvement of patient outcomes.

[bones698] 12/11/2024 10:43

Short is closing they need to buy about another 2?5m shares to close . Last time they closed the share price rocketed . If your too simple to understand what's going on I suggest you shut up .

Meanwhile those with a brain will buy and make money again .

[hazl] 12/11/2024 10:36

Note commercial sales .

Further note....

'test of choice'.




'First UK commercial sales of the Genedrive® CYP2C19-ID Kit




genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that
following the UK’s National Institute for Health and Care Excellence (“NICE”) final published guidance that CYP2C19
genotyping should be used to guide clopidogrel use after Ischaemic Stroke (“IS”) or Transient Ischaemic Attack
(“TIA”), and that the Genedrive® CYP2C19-ID test should be used as the test of choice for point of care strategies1,
an initial order for the CYP2C19-ID Kit and instruments has been received (c.£0.1M) to support an implementation
assessment at Greater Manchester’s Comprehensive Stroke Centre (“CSC”).
Hyperacute Stroke units (“HASU”) are part of the UK’s Integrated Stroke Delivery Network, where care typically
covers the first 72 hours after admission, with the aim that every patient with acute stroke should gain rapid access
to a stroke unit in under four hours and receive an early multidisciplinary assessment2. Greater Manchester CSC is
the largest and busiest HASU in England with more than 2,000 stroke patient admissions per annum and is situated
within the Manchester Centre for Clinical Neurosciences (“MCCN”) at Salford Royal Hospital, part of Northern Care
Alliance NHS Foundation Trust. The implementation assessment’s aim is to establish the benefit for patients across
Greater Manchester.'


h

[hazl] 12/11/2024 10:32

The sales we have had announced back in August are just the start, in my opinion.

[batiatus] 12/11/2024 10:21

Another day without sales or profit, only cash burn.

(G)enuinely (D)on't (R)ecommend

[hazl] 12/11/2024 10:12

Good to see GDR share price fighting against the low start.
That was due in part to the UT trade at close yesterday, in my opinion .

IMO

[hazl] 12/11/2024 10:10

From the NHS itself.

[hazl] 12/11/2024 09:54

Be aware the sister thread has degenerated again.

We will try to keep to facts on this board.